David Lamond Net Worth

The estimated Net Worth of David Lamond is at least $2.13 Million dollars as of 20 May 2022. Mr. Lamond owns over 66,500 units of Cortexyme Inc stock worth over $2,101,162 and over the last 6 years he sold CRTX stock worth over $0. In addition, he makes $33,750 as Independent Director at Cortexyme Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lamond CRTX stock SEC Form 4 insiders trading

David has made over 6 trades of the Cortexyme Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 66,500 units of CRTX stock worth $210,805 on 20 May 2022.

The largest trade he's ever made was buying 66,500 units of Cortexyme Inc stock on 20 May 2022 worth over $210,805. On average, David trades about 17,830 units every 46 days since 2019. As of 20 May 2022 he still owns at least 1,077,519 units of Cortexyme Inc stock.

You can see the complete history of Mr. Lamond stock trades at the bottom of the page.

David Lamond biography

David A. Lamond J.D. serves as Independent Director of the Company. Mr. Lamond has served as the president of En Pointe LLC, an investment firm, since 2016. He served as the President, Chief Executive Officer and Chief Investment Officer of Lamond Capital Partners LLC from 2011 to 2016. He also serves on the board of directors of Applied Molecular Transport, a biotechnology company. Lucira Health Inc, a molecular diagnostics company, Inquis Medical, a medical device company and Genelpis SAS, a biotech company. He previously served on the board of Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. In addition, he serves on the board of directors of two non-profit organizations, Tipping Point Community and Ubuntu Pathways. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.

What is the salary of David Lamond?

As the Independent Director of Cortexyme Inc, the total compensation of David Lamond at Cortexyme Inc is $33,750. There are 13 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.

How old is David Lamond?

David Lamond is 45, he's been the Independent Director of Cortexyme Inc since 2015. There are 18 older and no younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.

What's David Lamond's mailing address?

David's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Cortexyme Inc

Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.

What does Cortexyme Inc do?

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.

Complete history of Mr. Lamond stock trades at Cortexyme Inc and Applied Molecular Transport

Cortexyme Inc executives and stock owners

Cortexyme Inc executives and other stock owners filed with the SEC include:

• Michael Detke,
  Chief Medical Officer
• Margaret Mcloughlin,
  Independent Director
• Casey C. Lynch,
  Co-Founder, Chairman, Pres & CEO
• Christopher Senner,
  Independent Director
• Dr. Michael J. Detke M.D., Ph.D.,
  Chief Medical Officer
• Dr. Leslie J. Holsinger Ph.D.,
  Exec. VP of R&D
• Casey Lynch,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Christopher P. Lowe M.B.A.,
  COO, CFO & Treasurer
• Caryn Gordon McDowell,
  Chief Legal & Admin. Officer and Corp. Sec.
• Stephen Dominy,
  Co-Founder, Chief Scientific Officer, Director
• Una Ryan,
  Lead Independent Director
• Kevin Young,
  Independent Director
• Christopher Lowe,
  Chief Financial Officer, Treasurer
• David Lamond,
  Independent Director
• Dr. Stephen S. Dominy,
  Co-Founder, Chief Scientific Officer & Director
• Caryn McDowell,
  Chief Legal and Administrative Officer, Corporate Secretary
• Leslie Holsinger,
  Executive Vice President - Preclinical Development
• Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D.,
  Chief Medical Officer
• Brendan Hannah M.B.A.,
  Chief Bus. Officer
• Dr. Dirk Thye M.D.,
  CEO & Director
• Mary Ellen Sillivos,
  VP of HR
• Stacy Roughan,
  VP of Corp. Communications & IR
• Ted Monohon,
  VP of Fin. & Chief Accounting Officer
• Ansbert Gadicke,
  
• James B Tananbaum,
  Director
• Christopher T Phd Walsh,
  Director
• Richard W Dugan,
  Director
• M Cory Zwerling,
  Director
• Luke Evnin,
  
• Michael Steinmetz,
  
• Kurt Wheeler,
  
• Nicholas Galakatos,
  Director
• Bioventures Ii Qp Lpmpm Bio...,
  
• Dana Charles Hilt,
  SVP of Clinical Develop. & CMO
• Philip S Low,
  Director
• Marwan Sabbagh,
  Director
• Brendan Hannah,
  Chief Business Officer
• Dirk Thye,
  Chief Executive Officer
• Karen L. Smith,
  Chief Medical Officer
• Laura Shawver,
  Director
• Michael Thomas Heffernan,
  Director
• Andreas Maetzel,
  VP, Clinical and Regulatory
• Robert Stephan,
  Director
• Alan Roberts,
  VP, Scientific Affairs
• Craig A Collard,
  President and CEO
• James A Harper,
  Director
• Ira Duarte,
  Principal Accounting Officer
• Alastair Stuart Mcewan,
  Director
• Farmaceutici Sp A Chiesi,
  10% owner
• Christopher George Codeanne,
  Director
• Joshua B Franklin,
  VP, Sales and Marketing
• Marco Vecchia,
  Director
• Kenneth Mc Bean,
  President
• Anton Giorgio Failla,
  Director
• Michael David Enright,
  Director
• Ventures, Inc.Takeda Pharma...,
  
• Paul D Rubin,
  President and CEO
• Inc Pfizer Ventures (Us) Ll...,
  
• Pierre Lamond Christine Lamond,
  
• Walter Newman,
  Chief Scientific Officer/VP RD
• Howland Shaw Warren,
  Director
• Frederick Finnegan,
  VP of Sales and Marketing
• Robert H Zeiger,
  Director
• Technology Ventures Vii Lp ...,
  
• Christopher Mirabelli,
  Director
• Ventures Vi Lphealthcare Pa...,
  
• Jean George,
  Director
• Ventures, Inc. Med Immune,
  10% owner
• Bioventures Iii Qp Lpmpm Bi...,
  
• Jean Advanced Technology Ve...,
  
• Frank E Thomas,
  CFO, VP Finance and Treasurer
• & Johnson Johnson & Johnson...,
  
• Alessandro Chiesi,
  Director
• Vincent T. Morgus,
  EVP, Finance and CFO
• Brian Dickson,
  Chief Medical Officer
• Steven Michael Lutz,
  Executive Vice President
• David Price,
  Chief Financial Officer
• Bio Pharma Holdings, Ltd. C...,
  10% owner
• Scott B Townsend,
  VP OF LEGAL AFFAIRS AND SEC.
• Jeffrey E Young,
  VP FINANCE, CAO AND TREASURER
• Trevor Phillips,
  COO, VP of Operations and Sec.
• George Arthur Esgro,
  Vice President Sales
• Chenyqua Michele Baldwin,
  Vice President Finance
• Thomas Patrick Kelly,
  CFO & SVP Finance & Corp. Dev,
• Capital Group, Llc Boeding ...,
  
• Kristen Gafric,
  SVP, Legal & Administration
• Inc Pfizer Strategic Invest...,
  
• Ted Monohon,
  Chief Accounting Officer & VP
• June Bray,
  Director